Shingles vaccine for people with chronic lymphocytic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is testing whether the Shingrix vaccine (which protects against shingles) works well and is safe in people with chronic lymphocytic leukemia (CLL). The vaccine may help boost your immune system's ability to fight off shingles, a common and painful infection for CLL patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CLL, small lymphocytic lymphoma, or a related early stage (MBL).
- You belong to one of these groups: early-stage disease, or active disease before starting treatment, or you've been on targeted therapy (like ibrutinib or venetoclax) for at least 6 months.
- You are 18 years or older.
- You are eligible for the Shingrix vaccine through the Italian health system.
- You have not had a shingles outbreak in the last 12 months, and you've never received Shingrix before.
- You are not pregnant, and you haven't had IVIG treatment or chemotherapy recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new shingles vaccine in people with psoriasis or myelofibrosis, some of whom take immune-modifying medications. Researchers want to understand how well the vaccine works and how the immune system responds in these groups.
This study tests how well the shingles vaccine works in people with weakened immune systems due to conditions like rheumatoid arthritis, cancer, or multiple sclerosis. It aims to see if the vaccine is safe and effective for these patients.
This study looks at how well the shingles vaccine works in people with autoimmune inflammatory diseases. Researchers want to make sure the vaccine provides good protection for patients whose immune systems are affected by their condition or treatment.
This study tests how well the shingles vaccine (Shingrix) works in people with lupus who take immune-suppressing medications. Researchers want to understand if the vaccine provides good protection in lupus patients, since their immune systems work differently.
This study offers the Shingrix shingles vaccine for free to adults with inflammatory rheumatic diseases. It compares how well the vaccine works in people taking immune-suppressing drugs versus those not taking them.
This Phase 4 study checks how safe a shingles vaccine (Shingrix, a non-live vaccine) is for adults with lupus. You might be invited if you have lupus and haven’t had certain shingles or chickenpox-related vaccines recently, and if your lupus symptoms and immune health meet the study rules.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.